ACHFF (Arch Biopartners) Institutional Ownership : 0.94% (As of Mar. 27, 2025)

View and export this data going back to 2009. Start your Free Trial

What is Arch Biopartners Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Arch Biopartners's institutional ownership is 0.94%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Arch Biopartners's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Arch Biopartners's Float Percentage Of Total Shares Outstanding is 0.00%.

Arch Biopartners Institutional Ownership Historical Data

The historical data trend for Arch Biopartners's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arch Biopartners Institutional Ownership Chart

Arch Biopartners Historical Data

The historical data trend for Arch Biopartners can be seen below:

	2019-03-31	2019-04-30
Institutional Ownership	0.94	0.94

Arch Biopartners Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Arch Biopartners Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arch Biopartners Inc (OTCPK:ACHFF) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

ARCH:Canada

Address

545 King Street West, Toronto, ON, CAN, M5V 1M1

Website

https://www.archbiopartners.com

Arch Biopartners Inc is a late-stage clinical trial company focused on preventing acute kidney injury and organ damage caused by inflammation. The company is developing a platform of novel drugs that target the dipeptidase-1 (DPEP1) inflammation pathway, which is prevalent in the kidneys, lungs, and liver.